newsfilter
← Latest News
GlobeNewswire·

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

  • Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) will host a conference call & live webcast at 4:30 p.m. ET on Tuesday, May 12, 2026.
  • The event will discuss first-quarter 2026 financial results ending March 31, 2026, & provide a corporate update.
  • Participants can join via telephone using 1-833-316-2483 (domestic) or 1-785-838-9284 (international) with conference ID "VERRICA".
  • A live audio webcast is available at www.verrica.com, with a replay archived for 90 days post-event.
  • Verrica's product YCANTH® (VP-102) is the first FDA-approved treatment for molluscum contagiosum in patients aged two & older.
  • YCANTH® is also in development to treat common warts.
  • Verrica holds a worldwide license with Lytix Biopharma AS to develop VP-315 (ruxotemitide) for non-melanoma skin cancers.
  • Investor contacts include Interim CFO John J Kirby & LifeSci Advisors' Kevin Gardner.